Podcasts about Nuance Communications

About Allison Stalla:Allison Stalla is a distinguished leader in the realm of healthcare technology, currently holding the position of Director of Clinical Applications at Microsoft Cloud for Healthcare. With a robust focus on reducing the documentation burdens faced by nursing clinicians, Allison utilizes cutting-edge AI technologies to enhance patient care and mitigate nurse burnout. Her comprehensive background includes significant contributions at Nuance Communications as the Principal of Client Insights, where she influenced healthcare strategy and client engagement. Allison is dedicated to advancing clinical applications that prioritize user-centric design, integrating AI into healthcare workflows, and driving digital transformation in healthcare settings.In her role at Microsoft, Allison emphasizes the importance of change management and data literacy for successful AI adoption in healthcare. She is deeply committed to fostering a collaborative environment where healthcare professionals can thrive. Her efforts are particularly concentrated on creating nurse-centered technologies, ensuring that the tools developed are not only innovative but also practical and beneficial for everyday clinical use. Through strategic partnerships and pilot programs, Allison's work at Microsoft continues to push the boundaries of what's possible in healthcare technology, ultimately aiming to improve patient outcomes and streamline clinical processes.Things You'll Learn:AI is significantly reducing documentation burdens for nurses, allowing them to focus more on patient care and reducing burnout.Despite concerns about AI replacing jobs, there's broad willingness across various age groups to adopt AI in nursing.Successful AI adoption in healthcare requires strong leadership support, effective change management, and enhanced data literacy among healthcare professionals.Involving nurses in the development and design process of AI tools is crucial for building trust and ensuring these tools meet their needs.Microsoft's collaboration with Nuance and nine development partners focuses on creating nurse-centered technologies, including piloting ambient voice technology to aid bedside documentation.Resources:Connect with and follow Allison Stalla on LinkedIn.Follow Microsoft on LinkedIn.Visit the Microsoft Cloud for Healthcare website and check out their blogs. 

pWotD Episode 2751: Microsoft Welcome to Popular Wiki of the Day, spotlighting Wikipedia's most visited pages, giving you a peek into what the world is curious about today.With 537,399 views on Tuesday, 12 November 2024 our article of the day is Microsoft.Microsoft Corporation is an American multinational corporation and technology company headquartered in Redmond, Washington. Its best-known software products are the Windows line of operating systems, the Microsoft 365 suite of productivity applications, the Azure cloud computing platform, and the Edge web browser. Its flagship hardware products are the Xbox video game consoles and the Microsoft Surface lineup of touchscreen personal computers. Microsoft ranked No. 14 in the 2022 Fortune 500 rankings of the largest United States corporations by total revenue; and it was the world's largest software maker by revenue in 2022 according to Forbes Global 2000. It is considered one of the Big Five American information technology companies, alongside Alphabet (parent company of Google), Amazon, Apple, and Meta (parent company of Facebook).Microsoft was founded in 1975 by Bill Gates and Paul Allen to develop and sell BASIC interpreters for the Altair 8800. It rose to dominate the personal computer operating system market with MS-DOS in the mid-1980s, followed by Windows. The company's 1986 initial public offering (IPO) and subsequent rise in its share price created three billionaires and an estimated 12,000 millionaires among Microsoft employees. Since the 1990s, it has increasingly diversified from the operating system market and has made several corporate acquisitions, the largest being the acquisition of Activision Blizzard for $68.7 billion in October 2023, followed by its acquisition of LinkedIn for $26.2 billion in December 2016, Nuance Communications for $16 billion in March 2022, and Skype Technologies for $8.5 billion in May 2011.As of 2015, Microsoft is market-dominant in the IBM PC compatible operating system market and the office software suite market, although it has lost the majority of the overall operating system market to Android. The company also produces a wide range of other consumer and enterprise software for desktops, laptops, tabs, gadgets, and servers, including Internet search (with Bing), the digital services market (through MSN), mixed reality (HoloLens), cloud computing (Azure), and software development (Visual Studio).Steve Ballmer replaced Gates as CEO in 2000 and later envisioned a "devices and services" strategy. This unfolded with Microsoft acquiring Danger, Inc. in 2008, entering the personal computer market for the first time in June 2012 with the launch of the Microsoft Surface, and later forming Microsoft Mobile through the acquisition of Nokia's devices and services division. Since Satya Nadella took over as CEO in 2014, the company has scaled back on hardware and instead focused on cloud computing, a move that helped the company's shares reach their highest value since December 1999. Under Nadella's direction, the company has also heavily expanded its gaming business to support the Xbox brand, establishing the Microsoft Gaming division in 2022, dedicated to operating Xbox in addition to its three subsidiaries (publishers). Microsoft Gaming is the third-largest gaming company in the world by revenue as of 2024.In 2018, Microsoft became the most valuable publicly traded company in the world, a position it has repeatedly traded with Apple in the years since. In April 2019, Microsoft reached a trillion-dollar market cap, becoming the third U. S. public company to be valued at over $1 trillion after Apple and Amazon, respectively. As of 2024, Microsoft has the third-highest global brand valuation.Microsoft has been criticized for its monopolistic practices and the company's software has been criticized for problems with ease of use, robustness, and security.Microsoft is one of only two U. S.-based companies that have a prime credit rating of AAA.Microsoft recognizes seven trade unions representing 1,750 workers in the United States at its video game subsidiaries Activision Blizzard and ZeniMax Media. U. S. workers have been vocal in opposing military and law-enforcement contracts with Microsoft. Bethesda Game Studios is unionized in Canada. Microsoft South Korea recognizes its union since 2017. German employees have elected works councils since 1998.This recording reflects the Wikipedia text as of 01:34 UTC on Wednesday, 13 November 2024.For the full current version of the article, see Microsoft on Wikipedia.This podcast uses content from Wikipedia under the Creative Commons Attribution-ShareAlike License.Visit our archives at wikioftheday.com and subscribe to stay updated on new episodes.Follow us on Mastodon at @wikioftheday@masto.ai.Also check out Curmudgeon's Corner, a current events podcast.Until next time, I'm neural Olivia.

Have you ever wondered what the future of entrepreneurship looks like in a world where artificial intelligence can take on the roles traditionally reserved for human employees? In this episode of The Angel Next Door Podcast, host Marcia Dawood sits down with AI expert Sharon Zhang to explore the transformative impact of AI on business and society. Sharon talks about the evolving landscape of AI and its potential to not only automate mundane tasks but also to foster new business models and opportunities for creative entrepreneurship.Sharon Zhang, who boasts over 16 years of experience in artificial intelligence, emerges as a compelling guest. She began her journey at the MIT CCL lab and has since ventured through various roles, from clinical decision-making at Nuance Communications to algorithm development for hedge funds. Since 2020, she has co-founded Personal AI, a platform that builds digital twins to augment individual lives. Sharon's extensive background provides a rich foundation for discussing AI's role in modern entrepreneurship.This episode is a must-listen as Sharon provides a comprehensive view of the AI ecosystem, breaking it down into essential components like AI chips, infrastructure, foundation models, and applications. She shines a light on data privacy and the significance of user sovereignty over personal data. Furthermore, Sharon shares insights on the financial challenges faced by AI startups, the strategic moves by industry giants like OpenAI and Microsoft, and the burgeoning field of AI agents capable of performing complex tasks. Whether you're an entrepreneur, an investor, or simply fascinated by AI, this episode offers a treasure trove of knowledge and foresight into the future of artificial intelligence and its profound implications. To get the latest from Sharon Zhang, you can follow her below!LinkedIn - https://www.linkedin.com/in/xiaoranz1986/ https://www.personal.ai/Use the code PODCAST50 for 50% of any personal plan for 30 days! Sign up for Marcia's newsletter to receive tips and the latest on Angel Investing!Website: www.marciadawood.comLearn more about the documentary Show Her the Money: www.showherthemoneymovie.comAnd don't forget to follow us wherever you are!Apple Podcasts: https://pod.link/1586445642.appleSpotify: https://pod.link/1586445642.spotifyLinkedIn: https://www.linkedin.com/company/angel-next-door-podcast/Instagram: https://www.instagram.com/theangelnextdoorpodcast/TikTok: https://www.tiktok.com/@marciadawood

In this episode Paul Visokey shares his journey of starting Stony Hill Advisors in 2010 and provides insights into how he helps small business owners prepare for and execute successful mergers and acquisitions. The discussion delves into the importance of succession planning, making businesses independent, and ensuring smooth transitions for employees. Paul emphasizes the need for advanced preparation, ideally over a thousand days, to address potential issues and maximize business value. The conversation also highlights the human-centric approach Stony Hill Advisors takes, focusing on both business and personal readiness of the owners for retirement and the future.   Episode Highlights: 02:26 The Importance of Succession Planning 03:44 Challenges and Solutions in Business Transitions 06:43 Ideal Clients and Market Focus 08:37 Preparing for a Successful Business Exit 09:34 The Thousand-Day Transition Plan 14:00 Real-Life Success Stories 19:18 Building Relationships and Marketing Strategies   Paul Visokey, CEO of Stony Hill Advisors, brings a wealth of experience in M&A advisory, business valuations, and exit planning for small businesses. With a background in marketing, business development, and IT from roles at ROLM, IBM, and Nuance Communications, he blends practical sales knowledge with technical expertise. Paul's Electrical Engineering, Computer Science, and MBA degrees drive his strategic approach, ensuring maximum value for clients. Certified in M&A, business brokerage, and value building, Paul coaches business owners to achieve optimal outcomes. Outside of work, he enjoys golf, bridge, and time with his family in Stamford, CT.   How to connect with Paul: Website: www.stonyhiilladvisors.com LinkedIn: https://www.linkedin.com/company/1149854/admin/dashboard/   For more insights: Follow me on my YouTube Channel: https://bit.ly/47GgMdn  Sign up for my Weekly Newsletter:  https://bit.ly/3T09kVc Sign up for my LinkedIn Newsletter: https://bit.ly/49SmRV3See omnystudio.com/listener for privacy information.

A member of the CHIME OTF speaks to a serial health IT entrepreneur to discuss his blueprint for innovation and funding for technology solutions that are addressing the opioid crisis. Moderator: Art Nicholas Chief Commercial Officer, Interlace Health and Member, CHIME Opioid Task Force Experienced healthcare software leader, executive at both startups as well as industry leaders such as Nuance Communications. Guest: David Reeser Founder and CEO, OpiAID A serial entrepreneur, inventor, and mentor to startup founders. OpiAID is a data science company making the treatment of substance use disorder safer and more effective. What you'll learn: - The process of applying and receiving a SBIR (Small Business Innovation) grant and its impact on one serial entrepreneur's opioid solution. - Why a business would want to apply for an SBIR grant and what kind of work it funds. - Private vs. public sources of funding options and what they might look like for bringing opioid solutions to market. - What kinds of support and partnerships are necessary for a healthcare IT start-up venture to succeed. - How the innovation and funding process helped to develop OpiAID, a technology solution created to address the opioid crisis. - The impact of this solution and how it's being measured - Mentor advice from a successful entrepreneur to other founders/entrepreneurs.

Dr. Karen Litzy interviews Dr. Jared Pelo, co-founder of Bionic Health, about leveraging AI in medicine to improve patient care and physician-patient connections. Dr. Pelo shares his journey from emergency medicine to founding Bionic Health, driven by a desire to address healthcare issues proactively rather than reactively. Tune in to learn more about the intersection of AI and medicine in revolutionizing healthcare practices.   Time Stamps:  00:00:02 - Introduction and Guest Welcome 00:00:42 - Dr. Jared Pelo's Background 00:01:59 - Transition to AI and Medicine 00:03:04 - Personal Tragedy and Founding Bionic Health 00:04:20 - Role of AI in Longevity Medicine 00:06:10 - Practical Application of AI in Healthcare 00:10:18 - AI and Physician Collaboration 00:12:10 - Human Connection in Healthcare 00:13:23 - Benefits of AI for Patients 00:16:38 - Longevity Medicine Explained 00:19:17 - Anecdotes and Studies on Longevity 00:23:20 - Bionic Health's Approach to Longevity 00:24:20 - Importance of Exercise and Lifestyle 00:27:05 - Education and Preventative Measures 00:29:07 - Take-Home Message 00:30:47 - How to Learn More About Bionic Health 00:31:28 - Advice to 20-Year-Old Self 00:32:12 - Conclusion and Farewell   More About Dr. Jared Pelo: Jared Pelo, MD, Chief Medical Officer and Co-Founder of Bionic Health   Dr. Jared Pelo trained and worked in emergency medicine before founding iScribes, an early ambient AI health tech company. iScribes was acquired by Nuance Communications a Microsoft Company and was developed into Dragon Ambient eXperience. Dr Pelo started Bionic Health after a family tragedy and being inspired by the power of AI in medicine. Passionate about AI in medicine and preventive medicine, Dr. Pelo advocates using advanced AI tools and compassion to enhance patient-physician connection and patient care.   Resources from this Episode: Bionic Health Website Dr. Pelo on LinkedIn Dr. Pelo on YouTube   Jane Sponsorship Information: Book a one-on-one demo here Mention the code LITZY1MO for a free month   Follow Dr. Karen Litzy on Social Media: Karen's Twitter Karen's Instagram Karen's LinkedIn   Subscribe to Healthy, Wealthy & Smart: YouTube Website Apple Podcast Spotify SoundCloud Stitcher iHeart Radio

EPISODE 170 OF GROWING OLDER LIVING YOUNGER focuses on the transformative potential of AI in healthcare, emphasizing its ability to enhance patient care, diagnostics, and treatment outcomes.  Jared Pelo, MD  shares his experience in integrating AI into medical practice, focusing on prevention and personalized health. The conversation highlights the importance of considering the whole person, mind, body and their environment, in pursuit of optimal health.Jared Pelo is the Chief Medical Officer and Co-Founder of Bionic Health. He trained and worked in emergency medicine before founding iScribes, an early ambient AI health tech company, later acquired by Nuance Communications, a Microsoft Company. Dr Pelo started Bionic Health after a family tragedy and being inspired by the power of AI in medicine. Passionate about AI in medicine and preventive medicine, Dr. Pelo advocates using advanced AI tools and compassion to enhance patient-physician connection and patient care. Episode Timeline  0.01 Introduction to AI in healthcare with a former emergency medicine physician 7:36 The evolution of AI from rule-based systems to neural networks 13:25 Generative models of AI in medicine and preventative care. 20:00 Using AI in healthcare to personalize risk assessment and prevention.    26:37 Aging, health, and prevention in functional medical practice Learn more about about Dr. Jared Pelo and Bionic Health https://www.youtube.com/channel/UCX3PwfLyeN_1xm5e43wtUXw https://twitter.com/Bionic_Health_ https://www.linkedin.com/company/89906497/admin/dashboard/ https://www.instagram.com/bionichealth/ https://www.facebook.com/people/Bionic-Health/61553970021666/?paipv=0&eav=AfYVP5XBz1GD_tK5dIrO9I0bg1uMBx8wC5fagyil078t_KPWeAwDVpnELlE60_0VAZQ&_rdr Get to know Your Host: Dr. Gillian Lockitch https://linktr.ee/askdrgill Download your free Program Overview of  Memory Boosting Mastery: Say Goodbye to Senior Moments:     For more information schedule a free Discovery Call with Dr. Gill And if you have not already done so, follow, rate and review this Growing Older Living Younger podcast.

The Department of Veterans Affairs (VA) is pushing forward with its artificial intelligence initiatives by awarding sole-source contracts to Abridge AI, Inc. and Nuance Communications, Inc. These contracts aim to develop AI-driven healthcare dictation tools. The pilot program will employ ambient AI technology to transcribe clinical encounters and seamlessly generate medical notes. This initiative is part of the VA's broader strategy to enhance healthcare delivery by integrating these tools with its electronic health record system, thereby improving efficiency and reducing manual data entry. Additionally, the Social Security Administration (SSA) is transitioning its long-time online account users to Login.gov, a centralized identity verification service managed by the General Services Administration (GSA). This transition affects users who created accounts before September 2021. SSA Commissioner Martin O'Malley emphasized that this move aims to enhance security and streamline access to SSA services. Over five million users have already made the switch, reflecting a broader federal effort to standardize authentication processes across agencies. Hear more on today's episode of The Daily Scoop Podcast.

Drex dives into the recent Supreme Court decision to overturn the Chevron Doctrine and its profound implications on healthcare cybersecurity regulations. Explore how this ruling could slow down regulatory processes when speed is crucial. Drex also discusses a major data breach involving Geisinger Health System and Nuance Communications, and wraps up with a look into the emerging digital afterlife industry, where generative AI brings back digital versions of the deceased. Remember, Stay a little paranoid.Subscribe: https://www.thisweekhealth.com/subscribe/Linkedin: https://www.linkedin.com/company/ThisWeekHealthTwitter: https://twitter.com/thisweekhealthDonate: Alex's Lemonade Stand: Foundation for Childhood Cancer - https://www.alexslemonade.org/mypage/3173454

In this episode of the Great Women in Compliance podcast, Hemma and Ellen host a roundtable with Hope Anderson, a partner in White & Case's Data, Privacy & Cybersecurity Practice, and Jean Liu, Assistant General Counsel, Privacy, Safety, and Regulatory Affairs who joined Microsoft in 2023 as part of the Nuance Communications, Inc. acquisition.    Together, Hope and Jean have a wealth of experience advising on privacy, AI, and data governance compliance issues and they are well positioned to leverage this experience in the wake of a rapidly evolving regulatory landscape. Hemma and Ellen didn't waste a minute mining these two experts for practical tips and recommendations for those of us looking to get smart quick and grapple with what seems like a behemoth task of keeping up with developments in the technology and the legislation, while at the same time, making sure we don't get left behind in learning to leverage AI in our own functions. Join us for an engaging ride through the ups and downs of privacy and AI compliance, and be inspired as we were by the great opportunities to develop new and exciting use cases while mitigating risk and the chance to unlock the power of responsible and ethical AI for our businesses.  Key Highlights Getting up to speed with rapidly evolving regulatory landscape The role of AI principles vs policies and procedures Human Rights, Bias, and AI Keeping the “Human in the Loop” Thoughts on a US Federal AI or Privacy Law Leveraging AI for Ethics and Compliance Key resources and recommendations Resources Join the Great Women in Compliance community on LinkedIn here.

Gretchen Herault is Chief Privacy Officer at Randstad USA and the global job board Monster.com. She has held several privacy leadership roles, including Chief Privacy Officer at Haven Healthcare, HIPAA Privacy Officer at GE Healthcare, and Chief Privacy Officer of Nuance Communications. In this episode… Since the introduction of CCPA and as of this recording there are just under two dozen privacy laws either signed or about to be, altering how companies manage consumer data.As compliance becomes increasingly urgent, how can businesses structure their privacy programs around these laws? Gretchen Herault manages Randstad USA's privacy program, collaborating with a cross-functional team of legal and business professionals to develop comprehensive strategies and operational solutions. As a result, Randstad's privacy program takes a proactive approach and adapts to new regulations by aligning with California's strict privacy standards. This simplifies compliance efforts and prepares the company for upcoming laws. In today's She Said Privacy/He Said Security episode, Jodi and Justin Daniels engage in a thought-provoking conversation with Gretchen Herault, the Chief Privacy Officer of Randstad USA and Monster.com, about building and operationalizing privacy programs. They discuss how to develop privacy programs under a growing number of privacy laws, regulating company AI use, and Gretchen's advice for evaluating and building privacy teams.

March 22: In this Interview in Action at HIMSS 2024, Bill Russell interviews Kenneth Harper, VP and GM from Nuance Communications. Harper discusses the revolutionary impact of DAX Copilot in healthcare documentation, highlighting its seamless integration into Epic and its ability to save clinicians valuable time. But with the democratization of technology, how do we ensure quality and accuracy? As organizations rush to adopt similar solutions, what distinguishes true innovation from mere imitation? Moreover, as AI continues to evolve, what new frontiers lie ahead in healthcare augmentation and automation?

Dave is joined by Peter Mahoney, CMO of GoTo. Prior to that, he was the CMO at Nuance Communications and later founded Plannuh, which was acquired by Planful. Peter is the author of The Next CMO: A Guide to Operational Marketing Excellence, a book that teaches you how to form marketing goals, create a strategy, build a plan, craft impactful campaigns, optimize budgetary spending, and measure true ROI.In this episode, they discuss:Why Peter got back into the game as CMO after being CEO at PlannuhHow he landed his role at GoToWhat his strategy has been coming into a new company as CMO (and a company that has been around for a while)How do you make changes in a marketing org?What does his team look like at GoTo? What are they focused on?Peter is a master at marketing strategy and execution, and this episode will teach you a lot of that. Enjoy.Timestamps(00:00) - - Intro & balancing business and personal aspirations (08:26) - - Journey to being a CMO (13:58) - - Navigating company restructuring (15:16) - - Streamlining marketing operations (20:10) - - Expectations for rapid change in marketing leadership (21:46) - - The importance of role transition (28:23) - - Navigating layoffs and leadership (31:56) - - Past mistakes in hiring practices (32:48) - - Embracing diversity for better problem-solving (37:48) - - Strategy: Navigating resources, blind spots, and team dynamics (41:10) - - How to balance strategy and execution (44:43) - - How to build long-term vision and short-term plans in marketing (46:13) - - Brand strategy

Today's guest is Laurie Prescott, RN, MSN, CCDS, CCDS-O, CDIP, CRC, ACDIS' interim director and HCPro's CDI education director. Today's show is part of the “Talking CDI” series. In every episode of this series, ACDIS Director of Programming Rebecca Hendren is joined by a member of the ACDIS Advisory Board, one of our expert Boot Camp instructors, or an expert on a particular area to discuss a topic pertinent to today's CDI profession. Our intro and outro music for the ACDIS Podcast is “medianoche” by Dee Yan-Kay and our ad music is “Take Me Higher” by Jahzzar, both obtained from the Free Music Archive. Have questions about today's show or ideas for a future episode? Contact the ACDIS team at info@acdis.org. Want to submit a question for a future "listener questions" episode? Fill out this brief form!  Today's sponsor: Today's show is brought to you by Nuance Communications, a Microsoft Company. Nuance Communications is a technology pioneer with market leadership in conversational AI and ambient intelligence, and a full-service partner trusted by 77% of U.S. hospitals and 85% of the Fortune 100 companies worldwide. Now a Microsoft company, Nuance brings industry-leading AI and deep vertical expertise to address your biggest challenges and accelerate healthcare outcomes. Nuance meets you where you are in your CDI journey, with AI‑driven solutions that meet your needs. Recently named 2024 Best in KLAS for clinical documentation integrity, CDE One provides in‑workflow intelligence that keeps the patient at the center of the story, supporting quality outcomes and appropriate reimbursement. Optimize your CDI program and maximize resources with CDE One's AI-powered encounter prioritization, workflow, analytics, and services, delivered in your current workflows and hosted on HITRUST CSF-certified Microsoft Azure for end-to-end security, privacy, and compliance. Visit www.nuance.com for more information. CEU info: Each ACDIS Podcast episode now offers 0.5 ACDIS CEUs which can be used toward recertifying your CCDS or CCDS-O credential for those who listen to the show in the first two days from the time of publication. To receive your 0.5 CEUs, go to the show page on acdis.org, by clicking on the “ACDIS Podcast” link located under the “Resources” tab. To take the evaluation, click the most recent episode from the list on the podcast homepage, view the podcast recording at the bottom of that show page, and click the live link at the very end after the music has ended. Your certificate will be automatically emailed to you upon submitting the brief evaluation. (Note: If you are listening via a podcast app, click this link to go directly to the show page on acdis.org: LINK) Note: To ensure your certificate reaches you and does not get trapped in your organization's spam filters, please use a personal email address when completing the CEU evaluation form. The cut-off for today's episode CEU is Friday, March 29, at 11:00 p.m. eastern. After that point, the CEU period will close, and you will not be eligible for the 0.5 CEUs for this week's episode. ACDIS update: Watch the tour of the new ACDIS website menu navigation! (https://ow.ly/coxA50QZ94R) Send your article ideas to Jess Fluegel and Linnea Archibald by April 1 for the May/June edition of the CDI Journal! (jess.fluegel@hcpro.com; linnea.archibald@hcpro.com) Respond to the 2024 ACDIS Membership Survey (whether or not your currently a member) by April 12! (https://www.surveymonkey.com/r/2024-ACDIS-membership-survey) Take a look at the 2024 conference agenda and register today! (https://ow.ly/73vw50QwrJv) The current copy of the Code of Ethics is here: https://acdis.org/membership/ethics. The updated version discussed in today's program is being finished and will be published soon. We will announce it's publication in CDI Strategies.

Today's guest is Jorde Spitler, BSN, RN, CCDS, manager of CDI at Dayton Children's Hospital in Ohio. Today's show is part of the “Leadership with Linnea” series. In every episode of this series, Associate Editorial Director Linnea Archibald is joined by one guest from the ACDIS Leadership Council ranks or a contributor from one of ACDIS' publications to discuss a topic relevant to leaders in the industry, whether or not they currently hold a traditional management title. Our intro and outro music for the ACDIS Podcast is “medianoche” by Dee Yan-Kay and our ad music is “Take Me Higher” by Jahzzar, both obtained from the Free Music Archive. Have questions about today's show or ideas for a future episode? Contact the ACDIS team at info@acdis.org. Want to submit a question for a future "listener questions" episode? Fill out this brief form!  Today's sponsor: Today's show is brought to you by Nuance Communications. Nuance Communications is a technology pioneer with market leadership in conversational AI and ambient intelligence, and a full-service partner trusted by 77% of U.S. hospitals and 85% of the Fortune 100 companies worldwide. Now a Microsoft company, Nuance brings industry-leading AI and deep vertical expertise to address your biggest challenges and accelerate healthcare outcomes. Nuance meets you where you are in your CDI journey, with AI‑driven solutions that meet your needs. Recently named 2024 Best in KLAS for clinical documentation integrity, CDE One provides in‑workflow intelligence that keeps the patient at the center of the story, supporting quality outcomes and appropriate reimbursement. Optimize your CDI program and maximize resources with CDE One's AI-powered encounter prioritization, workflow, analytics, and services, delivered in your current workflows and hosted on HITRUST CSF-certified Microsoft Azure for end-to-end security, privacy, and compliance. Visit www.nuance.com for more information. CEU info: Each ACDIS Podcast episode now offers 0.5 ACDIS CEUs which can be used toward recertifying your CCDS or CCDS-O credential for those who listen to the show in the first two days from the time of publication. To receive your 0.5 CEUs, go to the show page on acdis.org, by clicking on the “ACDIS Podcast” link located under the “Resources” tab. To take the evaluation, click the most recent episode from the list on the podcast homepage, view the podcast recording at the bottom of that show page, and click the live link at the very end after the music has ended. Your certificate will be automatically emailed to you upon submitting the brief evaluation. (Note: If you are listening via a podcast app, click this link to go directly to the show page on acdis.org: https://acdis.org/acdis-podcast/pediatric-deep-dive-behavioral-health-reviews) Note: To ensure your certificate reaches you and does not get trapped in your organization's spam filters, please use a personal email address when completing the CEU evaluation form. The cut-off for today's episode CEU is Friday, March 15, at 11:00 p.m. eastern. After that point, the CEU period will close, and you will not be eligible for the 0.5 CEUs for this week's episode. ACDIS update: Take a look at the 2024 conference agenda and register today! (https://ow.ly/73vw50QwrJv) (Note that hotel information is in the “Location” tab.) Read the March/April edition of the CDI Journal focused on expansion and opportunities in CDI! (https://ow.ly/cVx750QRiJJ) Send your article ideas to Jess Fluegel and Linnea Archibald by April 1 for the May/June edition of the CDI Journal! (jess.fluegel@hcpro.com; linnea.archibald@hcpro.com)

Today's guest is Katherine Parsley, MSN, RN, CPHQ, CCDS, CDI manager at Providence Health & Services in Oregon. Today's show is hosted by ACDIS Associate Editorial Director Linnea Archibald, Director of Programming Rebecca Hendren, Editor and Product Coordinator Karla Kozak, and Associate Editor Jess Fluegel. The show provides a glimpse behind the scenes of all things ACDIS in a more casual, conversational format than our other podcast series.  Our intro and outro music for the ACDIS Podcast is “medianoche” by Dee Yan-Kay and our ad music is “Take Me Higher” by Jahzzar, both obtained from the Free Music Archive. Have questions about today's show or ideas for a future episode? Contact the ACDIS team at info@acdis.org. Want to submit a question for a future "listener questions" episode? Fill out this brief form!  Today's sponsor: Today's show is brought to you by Nuance Communications. Nuance Communications is a technology pioneer with market leadership in conversational AI and ambient intelligence, and a full-service partner trusted by 77% of U.S. hospitals and 85% of the Fortune 100 companies worldwide. Now a Microsoft company, Nuance brings industry-leading AI and deep vertical expertise to address your biggest challenges and accelerate healthcare outcomes. Nuance meets you where you are in your CDI journey, with AI‑driven solutions that meet your needs. Recently named 2024 Best in KLAS for clinical documentation integrity, CDE One provides in‑workflow intelligence that keeps the patient at the center of the story, supporting quality outcomes and appropriate reimbursement. Optimize your CDI program and maximize resources with CDE One's AI-powered encounter prioritization, workflow, analytics, and services, delivered in your current workflows and hosted on HITRUST CSF-certified Microsoft Azure for end-to-end security, privacy, and compliance. Visit www.nuance.com for more information. CEU info: Each ACDIS Podcast episode now offers 0.5 ACDIS CEUs which can be used toward recertifying your CCDS or CCDS-O credential for those who listen to the show in the first two days from the time of publication. To receive your 0.5 CEUs, go to the show page on acdis.org, by clicking on the “ACDIS Podcast” link located under the “Resources” tab. To take the evaluation, click the most recent episode from the list on the podcast homepage, view the podcast recording at the bottom of that show page, and click the live link at the very end after the music has ended. Your certificate will be automatically emailed to you upon submitting the brief evaluation. (Note: If you are listening via a podcast app, click this link to go directly to the show page on acdis.org: LINK) Note: To ensure your certificate reaches you and does not get trapped in your organization's spam filters, please use a personal email address when completing the CEU evaluation form. The cut-off for today's episode CEU is Friday, March 1, at 11:00 p.m. eastern. After that point, the CEU period will close, and you will not be eligible for the 0.5 CEUs for this week's episode. ACDIS update: Respond to the 2024 ACDIS Membership Survey by March 8 and be entered to win a giveaway! (https://www.surveymonkey.com/r/2024-ACDIS-membership-survey) Subscribe to CDI Strategies to read about the new edition of the CDI Journal when it's available! (https://ow.ly/7XWF50QEe45) Send your article ideas to Jess Fluegel and Linnea Archibald by April 1 for the May/June edition of the CDI Journal! (jess.fluegel@hcpro.com; linnea.archibald@hcpro.com) Take a look at the 2024 conference agenda and register today! (https://ow.ly/73vw50QwrJv) (Note that hotel information is in the “Location” tab.)

Today's guest is Sharme Brodie, RN, CCDS, CCDS-O, CRC, a CDI education specialist at HCPro/ACDIS. Today's show is part of the “Conversations with Karla” series. In every episode of this series, ACDIS Editor and Product Coordinator Karla Kozak is joined by a guest who's behind one of ACDIS' most popular and exciting ACDIS educational offerings to share their expertise. Our intro and outro music for the ACDIS Podcast is “medianoche” by Dee Yan-Kay and our ad music is “Take Me Higher” by Jahzzar, both obtained from the Free Music Archive. Have questions about today's show or ideas for a future episode? Contact the ACDIS team at info@acdis.org. Want to submit a question for a future "listener questions" episode? Fill out this brief form! Today's sponsor: Today's show is brought to you by Nuance Communications. Nuance Communications is a technology pioneer with market leadership in conversational AI and ambient intelligence, and a full-service partner trusted by 77% of U.S. hospitals and 85% of the Fortune 100 companies worldwide. Now a Microsoft company, Nuance brings industry-leading AI and deep vertical expertise to address your biggest challenges and accelerate healthcare outcomes. Nuance meets you where you are in your CDI journey, with AI‑driven solutions that meet your needs. Recently named 2024 Best in KLAS for clinical documentation integrity, CDE One provides in‑workflow intelligence that keeps the patient at the center of the story, supporting quality outcomes and appropriate reimbursement. Optimize your CDI program and maximize resources with CDE One's AI-powered encounter prioritization, workflow, analytics, and services, delivered in your current workflows and hosted on HITRUST CSF-certified Microsoft Azure for end-to-end security, privacy, and compliance. Visit www.nuance.com for more information. CEU info: Each ACDIS Podcast episode now offers 0.5 ACDIS CEUs which can be used toward recertifying your CCDS or CCDS-O credential for those who listen to the show in the first two days from the time of publication. To receive your 0.5 CEUs, go to the show page on acdis.org, by clicking on the “ACDIS Podcast” link located under the “Resources” tab. To take the evaluation, click the most recent episode from the list on the podcast homepage, view the podcast recording at the bottom of that show page, and click the live link at the very end after the music has ended. Your certificate will be automatically emailed to you upon submitting the brief evaluation. (Note: If you are listening via a podcast app, click this link to go directly to the show page on acdis.org: LINK) Note: To ensure your certificate reaches you and does not get trapped in your organization's spam filters, please use a personal email address when completing the CEU evaluation form. The cut-off for today's episode CEU is Friday, February 16, at 11:00 p.m. eastern. After that point, the CEU period will close, and you will not be eligible for the 0.5 CEUs for this week's episode. ACDIS update: Want to submit a question for a future "listener questions" episode? Fill out this brief form! (https://www.surveymonkey.com/r/ACDIS-podcast-listener-questions) ACDIS members can register for the February 22 Quarterly Conference Call! (https://ow.ly/sN8w50QwrHm) ACDIS members can read the brand new 2023 CDI Salary Survey report today! (https://ow.ly/KF9W50QwrIz) Take a look at the 2024 conference agenda and register today! (https://ow.ly/73vw50QwrJv)

The demand for ambient clinical voice solutions is gaining momentum and the market is quickly filling with vendors. Microsoft Nuance has been providing healthcare voice solutions for over two decades. How is the company leveraging that experience? Healthcare IT Today caught up with Peter Durlach, Chief Strategy Officer at Microsoft Life Sciences and Health to learn more about their ambient clinical voice solution. Durlach is responsible for developing and advancing Microsoft's healthcare strategy which includes Nuance Communications which Microsoft acquired in 2022. Durlach was an executive at Nuance for over 15 years. Learn more about DAX Copilot at https://www.nuance.com/healthcare/ambient-clinical-intelligence/explore-dax-for-clinicians.html Find more great health IT content at https://www.healthcareittoday.com/

Malgré une histoire chaotique et bien que la discipline existe depuis les années 50, l'«Intelligence Artificielle» est revenue en force dans la dernière décennie..Mais telle qu'elle est présentée, cette« Intelligence Artificielle »amène son lot de promesses irréalistes dignes des meilleurs films d'Hollywood, permettant à quelques charlatans de nous faire croire que les machines pourraient un jour prendre le pouvoir et nous réduire pratiquement à néant. Mais surtout de nous faire courir le risque, soit par peur, soit par dépit d'abandonner toutes les recherches dans ce domaine et de menacer les avancées dans des disciplines telles que le machine learning ou le deep learning qui seraient stoppées en plein élan, alors qu'elles n'en sont qu'à leurs balbutiements et qu'elles apporteront encore beaucoup à l'humanité... _ Luc Julia est directeur scientifique de Renault. Il a été directeur technique et vice-président pour l'innovation chez Samsung Electronics, a dirigé Siri chez Apple, été directeur technique chez Hewlett-Packard et a cofondé plusieurs start-ups dans la Silicon Valley. Lorsqu'il poursuivait ses recherches à SRI International, il a participé à la création de Nuance Communications, aujourd'hui leader mondial dans le domaine de la reconnaissance vocale. Chevalier de la Légion d'Honneur et membre de l'Académie nationale des technologies, il est diplômé en mathématiques et en informatique de l'Université Pierre et Marie Curie à Paris et a obtenu un doctorat en informatique à l'Ecole Nationale Supérieure des Télécommunications de Paris. Il est l'auteur du best-seller L'intelligence artificielle n'existe pas (First 2019), détient des dizaines de brevets et est reconnu comme l'un des 100 développeurs français les plus influents dans le monde numérique. Enregistré au Club 44 le 15 novembre 2023

AI Visualize, Inc. v. Nuance Communications, Inc.

This and all episodes at: https://aiandyou.net/ .   Radiology found itself in the crosshairs of the debate about AI automating jobs when in 2016 AI expert Geoffrey Hinton said that AI would do just that to radiologists. That hasn't happened - but will it?  To get to the bottom of this, I talked with Matthew Lungren, MD, Chief Medical Information Officer at Nuance Communications, a Microsoft company applying AI to healthcare workflows, and the name that comes at the top of the list when you look up #radiology and #AI. He also has a pediatric radiology practice at UCSF  and previously led the Stanford [University] Center for Artificial Intelligence in Medicine and Imaging. More recently he served as Principal for Clinical AI/ML at Amazon Web Services in World Wide Public Sector Healthcare. He has an impressive oeuvre of over 100 publications, including work on multi-modal data fusion models for healthcare applications, and new computer vision and natural language processing approaches for healthcare-specific domains. In this interview conclusion, we talk about the details of how AI including large language models can be an effective part of a radiologist's workflow how decisions about integrating AI into medicine can be made, and where we might be going with it in the future. All this plus our usual look at today's AI headlines. Transcript and URLs referenced at HumanCusp Blog.        

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. In recent biopharma news, Bavarian Nordic, a Dutch biotech company, has faced setbacks in its late-stage trials for respiratory syncytial virus (RSV) and COVID-19 vaccines. However, the company's CEO, Paul Chaplin, remains optimistic about the potential of the company in the travel vaccine market. Another development is that Eisai's Alzheimer's drug Leqembi has received approval in Japan and is still undergoing regulatory reviews in other countries. Intercept, a liver drug company, has agreed to a buyout by Alfasigma after failing to secure FDA approval for its research on nonalcoholic steatohepatitis (NASH). Bristol Myers' Opdivo has won a trial supporting its expanded use in lung cancer treatment, and new vaccines for respiratory syncytial virus (RSV) have the potential to be powerful tools, although their rollout poses challenges. In a merger deal worth $3 billion, HealthComp, a private equity-owned health benefits administrator, is set to merge with Virgin Pulse, a digital health and wellness company. The transaction aims to create an integrated platform for employer-sponsored health benefits, with investment firms joining forces for the merger. On the other hand, health insurer Centene is laying off 3% of its workforce due to challenges from Medicaid redeterminations and Medicare Advantage (MA) star ratings. Cano Health has sold its Texas and Nevada centers to a subsidiary of Humana for $67 million due to its worsening liquidity position. Lawmakers in Ohio have proposed minimum nurse-to-patient ratios to address nurse recruitment and retention and improve patient care. Nuance Communications has rolled out an automated clinical documentation tool called DAX Copilot, improving efficiency for healthcare providers.Roche has struck a deal to acquire preclinical RNA medicines from Ionis Pharmaceuticals, focusing on treatments for Alzheimer's and Huntington's diseases. Despite recent setbacks in phase 3 trials for respiratory syncytial virus (RSV) and COVID-19 vaccines, Bavarian Nordic CEO Paul Chaplin remains optimistic about the company's future in the travel vaccine market. ProQR's planned sale of eye drugs to Laboratoires Thea has fallen through due to certain ProQR personnel opting not to work for the French company. John Tsai has been appointed as CEO of UK heart drug startup Forcefield Therapeutics. The FDA staff have expressed "major concerns" with Brainstorm's ALS therapy. Obesity drugs like Ozempic and Wegovy could revolutionize the treatment of obesity and advance the understanding of the condition.Gilead Sciences has announced the discontinuation of a Phase III trial for its anti-CD47 antibody, magrolimab, in acute myeloid leukemia (AML). AbbVie has terminated its contract with Caribou Biosciences for the development of allogeneic CAR-T therapies. Astrazeneca and Bristol Myers Squibb have agreed to participate in the first round of price negotiations under the Medicare drug price negotiation program, despite filing lawsuits challenging the program. Italian pharma company Alfasigma has acquired Intercept Pharmaceuticals in an $800 million cash deal. Alto has reported positive Phase II data for post-traumatic stress disorder. Astellas has withdrawn its lawsuit challenging the inflation reduction act.BioNTech has announced plans to manufacture mRNA vaccines in Africa to address the vulnerability of relying on global supply chains for vaccine production. Proper chemical procurement is emphasized to avoid disruptions in the chemical supply chain for research and development (R&D) and drug manufacturing. AbbVie has terminated its contract with Caribou Biosciences as part of its strategy to cull cancer pipelines. AstraZeneca and Bristol Myers Squibb have reluctantly agreed to participate in the Medicare drug price negotiation program. Immunovant's stock has soared following positive Phase

This and all episodes at: https://aiandyou.net/ .   Radiology found itself in the crosshairs of the debate about AI automating jobs when in 2016 AI expert Geoffrey Hinton said that AI would do just that to radiologists. That hasn't happened - but will it?  To get to the bottom of this, I talked with Matthew Lungren, MD, Chief Medical Information Officer at Nuance Communications, a Microsoft company applying AI to healthcare workflows, and the name that comes at the top of the list when you look up #radiology and #AI. He also has a pediatric radiology practice at UCSF  and previously led the Stanford [University] Center for Artificial Intelligence in Medicine and Imaging. More recently he served as Principal for Clinical AI/ML at Amazon Web Services in World Wide Public Sector Healthcare. He has an impressive oeuvre of over 100 publications, including work on multi-modal data fusion models for healthcare applications, and new computer vision and natural language processing approaches for healthcare-specific domains. The basis for Hinton's assertion was that AI can be trained to find tumors, for instance, in CT scans, and we know how good AI is at image analysis when it's got lots of labeled data to be trained on, and we certainly have that with CT scans.  We get to find out what's real about AI in #medicine in this episode. All this plus our usual look at today's AI headlines. Transcript and URLs referenced at HumanCusp Blog.        

July 14: Today on TownHall Brett Oliver, Family Physician and Chief Medical Information Officer at Baptist Health speaks with Matt Lungren, Chief Medical Information Officer at Nuance Communications, a Microsoft Company. How can generative AI revolutionize healthcare, specifically in terms of the reception and experience so far with Nuance and the Dragon Ambient eXperience (DAX)? What are the misconceptions surrounding the use of generative AI, particularly in the context of ChatGPT? What are the most exciting use cases for generative AI in healthcare, and how can it transform tasks such as text summarization, knowledge retrieval, and analysis of medical literature? How can healthcare organizations navigate the regulatory landscape and ensure the safe and responsible use of AI algorithms, particularly in terms of continuous learning, monitoring, and evaluation?Subscribe: This Week HealthTwitter: This Week HealthLinkedIn: Week HealthDonate: Alex's Lemonade Stand: Foundation for Childhood Cancer

Today, we're excited to get to know Alexandre Lebrun, CEO and Cofounder of Nabla, a personalized AI assistant for doctors. Before founding Nabla, Alex was the Head of Engineering at Facebook AI research for almost four years, and is a seasoned entrepreneur, having sold his previous companies Wit.ai, an AI platform that makes it easy to build apps that understand natural human language, to Facebook in 2015 and VirtuOz, a customer service chatbot, to Nuance Communications in 2012. In this episode, Alexandre shares his experiences after 22 years and founding 3 startups, why proprietary data is more important than ever for defensibility, tactics on GTM and customer focus specific to healthcare buyers, and opportunities and safety for generative AI in healthcare.

Peter Durlach grew up around computers and was exposed to innovative technology at an early age by his father, who helped run a lab in the electronics department at MIT. After graduating college in the 1980s, Peter caught the entrepreneurial bug way before it was cool, and was employee number four at a company developing the first voice user interface for the Macintosh.Peter's work put him at the center of bringing voice recognition and artificial intelligence (AI) to healthcare – work he continues today as EVP and Chief Strategy officer at Nuance Communications, a Microsoft Company.At Articulate Systems, the first voice recognition company Peter helped build, he and his team eventually recognized that 60% of their user base was physicians dictating medical notes. He helped pivot the company to focus exclusively on healthcare and build the technology that became PowerScribe, a solution still used by most radiologist today.Through acquisitions, Articulate Systems eventually became Nuance. After some time away from the company as a software consultant and running an AI-powered contact center business he sold to Microsoft, Peter was recruited back to Nuance in 2006 to create its healthcare division. By 2019, Nuance was focused on the healthcare and customer engagement market, and in 2022 was acquired by Microsoft for $20 billion.In this episode of Healthcare is Hard, Keith Figlioli builds on earlier conversations with guests like Mayo's John Halamka and Advocate's Rasu Shrestha to unpack the hype around AI in healthcare and understand what's real right now, and what will be in the future. Some of the issue Keith and Peter discussed include:The AI adoption curve. Peter described the different adoption curves he sees for different use cases of AI in healthcare. He talks about how adoption of administrative use cases will happen much faster than clinical applications, and the factors that will influence adoption curves – from performance requirements to governance and patient safety.Use cases that matter. Nuance and Microsoft see one common theme for the application of AI in healthcare – that it should be a copilot and not an autopilot. In the near term, the major focus will be on automating administrative tasks in revenue cycle, payment integrity, documentation or other areas where there is a large labor expense. While automation may be able to accomplish 30% of the work in some areas, and 70% or more in others, the goal is reducing labor while maintaining human oversight. The bar is much higher for clinical use cases, but the same rules apply.Opportunities for startups. Peter shares lessons from his time at startups and the world's largest technology companies. He talks about how incumbents have an unfair advantage and a “right to win” because of their footprint with trusted clients, and how speed and nimbleness give startups an advantage. He says startups focusing on AI need to understand if they're supercharging an existing process, or creating a truly new paradigm, because understanding this will dictate their path to success.Governance – Peter talks about the governance and regulatory issues impacting AI adoption and the potential for certifying technology for specific uses, similar to what's required for pharmaceuticals or software as a medical device. He also discussed how Microsoft is building safeguards within its cloud infrastructure, allowing the ecosystem to stay focused on innovation.To hear Keith and Peter talk about these topics and more, listen to this episode of Healthcare is Hard: A Podcast for Insiders

Alex Lebrun is the Co-Founder and CEO of Nabla, an AI assistant for doctors. Prior to Nabla, he led engineering at Facebook AI Research. Alex founded Wit.ai, an AI platform that makes it easy to build apps that understand natural human language. Wit.ai was acquired by Facebook in 2015. Prior to Wit, Alex was the Founder and CEO of VirtuOz, the world pioneer in customer service chatbots, acquired by Nuance Communications in 2013. In Today's Episode with Alex Lebrun We Discuss: 1. Third Time Lucky and Lessons from Zuckerberg: How did Alex make his way into the world of startups with the founding of his first company? What worked with Alex's prior companies that he has taken with him to Nabla? What did not work that he has left behind? What were the single biggest takeaways for Alex from working with Mark Zuckerberg? How does Mark prepare for meetings? How does Mark negotiate so well? 2. Open vs Closed: Why does Alex believe the winning AI models will always be open? Why are open models not as transparent as people think they are? What are the biggest downsides to both open and closed models? Does Alex agree with Emad @ Stability that we will have "national data sets"? 3. Incumbent vs Startup: Who wins in the AI race; startups or incumbents? How important is access to proprietary data in winning in AI today? How does Alex respond to many VCs who suggest so many AI startups are merely "a thin layer on top of a foundational model"? Is that a fair critique? Which startups are best placed to challenge incumbents? Which incumbents have been most impressive in adopting AI into existing product suites? 4. Models 101: Size, Quality, Switching Costs: Why will the best companies switch the models that they use often? Will any models in action today be used in a year? How important is the size of the model? How will this change with time? In what way is new EU regulation around models going to harm European AI companies? 5. Location Matters: Who Wins: When looking at China, US and Europe, who is best placed to win the AI war? What are the biggest challenges Europe and China face? Why is the US best placed to win the AI race? What does it have to overcome first? If Alex were a politician, what would he do to ensure his country were best positioned?

In this episode, we are joined by Dr. Mark Snowise, CMIO at Berkshire Health Systems, and Dr. Robert Budman, CMIO at Nuance Communications, to discuss what healthcare big data comprises of, how big data can influence community chronic care patients, what CAPD is and a lot more. This episode is sponsored by Nuance.

In this special sponsored episode, we're discussing how ambient clinical intelligence can improve patient care and reduce clinician burnout. Our sponsor is the Dragon Ambient Experience, or DAX, an ambient clinical intelligence solution from Nuance Communications and Microsoft. I'm joined by Alfred Atanda Jr., MD, a pediatric orthopedic surgeon at Nemours Children's Health in Delaware. He is chief of the Center for Sports Medicine and the Chief of Clinician Experience, as well as an assistant professor of orthopedic surgery at the Sidney Kimmel Medical College at Thomas Jefferson University. We discuss the challenges of declining physician well-being and the potential solutions to address it. We'll also be discussing the impact of clinical documentation on burnout and how ambient clinical intelligence solutions like DAX can help alleviate these burdens. Join us as we discuss Dr. Atanda's experiences with burnout and clinical documentation and the benefits of using ambient clinical intelligence in their practice. Find out more at https://nuance.com/exploreDAX The Podcast by KevinMD is brought to you by the Nuance Dragon Ambient eXperience. With so many demands on their time, physicians today report record levels of burnout. Burnout is caused by many factors, one of which is clinical documentation. Studies indicate physicians spend two hours documenting care for every hour spent with patients. At Nuance, we are committed to helping physicians do what you love – care for patients – and spend less time on clinical documentation. The Nuance Dragon Ambient eXperience, or DAX for short, is an AI-powered, ambient clinical intelligence solution that automatically captures patient encounters securely and accurately at the point of care. Physicians who use DAX have reported a 50 percent decrease in documentation time and a 70 percent reduction in feelings of burnout, and 83 percent of patients say their physician is more personable and conversational. Rediscover the joy of medicine with clinical documentation that writes itself, all within the EHR. VISIT SPONSOR → https://nuance.com/exploreDAX SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RATE AND REVIEW → https://www.kevinmd.com/rate FOLLOW ON INSTAGRAM → https://www.instagram.com/kevinphomd FOLLOW ON TIKTOK → https://www.tiktok.com/@kevinphomd

P-Club Series continues with an interview with Leslie Matthews.  Leslie is a Channel Account Manager at Nuance Communications and is KILLING it. We talk to her about what makes her a perennial success in her role and how she exceeded TWO quotas in 2022.   We talk about work life balance, how to balance the time you are putting into your job especially working through partners, important sales activities, winning by selling through partners and more!Email us at stuffaboutsales@gmail.com

Dr Matthew Lungren is the Chief Medical Information Officer at Nuance Communications, a Microsoft Company. As a physician and clinical machine learning researcher, he maintains a part-time interventional radiology practice at UCSF while also serving as adjunct faculty for other leading academic medical centers including Stanford and Duke. Prior to joining Microsoft, Dr Lungren led the Stanford Center for Artificial Intelligence in Medicine and Imaging (AIMI). This interview offers great insight for anyone who is interested in non-traditional career paths in medicine at the cutting edge of the MaML space. I hope you all enjoy! and don't forget to follow us on twitter @themamlpodcast! contact@themamlpodcast.com Host: David Wu / Twitter: @davidjhwu Producer: Aaron Schumacher / Twitter: @a_schu95 Artwork & Video: Saurin Kantesaria Music: Caligula - Windows96. Used with Artist's Permission. 00:40 Could you tell us about your path coming to the intersection of medicine and artificial intelligence? 07:00 What literature are you a fan of? 08:50 Where will the next great American Author come from? 14:00 Tell us about your work with Nuance. 17:50 Could you tell us the background of Nuance and Dragon Dictation? 19:55 Tell us about Nuance products that are offered. 23:45 How much code should future physicians know? 28:30 What is a typical day like as chief medical officer 31:30 Do you have any advice for medical students interested in nontraditional career paths? 34:30 How do you balance clinical practice and industry work? 40:40 What are you excited about most in the next 10-20 years? 44:15 How has mentorship shaped your path? 46:08 What advice would you give yourself at your medical school graduation?

Dr. Rachna Shroff, chair-elect of the 2023 ASCO GI Cancers Symposium, and guest host Dr. Shaalan Beg discuss new research presented at GI23, including new data from SWOG 1815 in biliary tract cancers, advances in biomarker studies in mCRC such as the PARADIGM trial, and promising updates in ctDNA technology. She also highlights the exciting potential of AI in oncology. TRANSCRIPT Dr. Shaalan Beg:  Hello, and welcome to the ASCO Daily News Podcast. I'm Dr. Shaalan Beg, your guest host of the podcast today. I'm an adjunct associate professor at UT Southwestern's Simmons Comprehensive Cancer Center and vice president of Oncology at Science 37. Today we'll be discussing key abstracts and other highlights from the 2023 ASCO Gastrointestinal Cancer Symposium, which celebrated 20 years of transformative care in GI cancers. I'm delighted to welcome Dr. Rachna Shroff, the chair-elect of this milestone meeting. Dr. Shroff is the interim division chief of Hematology Oncology at the University of Arizona Cancer Center. She also serves as the associate dean for Clinical and Translational Research and is the chief of GI Medical Oncology. Our full disclosures are available in the transcript of this episode, and disclosures related to all episodes of the podcast are available on our transcripts at ASCO.org/podcasts. Dr. Shroff, it's great to have you back on the ASCO Daily News podcast. Dr. Rachna Shroff: Thank you so much for having me. I'm so excited to be here. Dr. Shaalan Beg: The ASCO GI Cancers Symposium has been heralded as one of the biggest conferences in the GI cancer space and has occupied this space for the past two decades. Some would say that this year's conference was probably the best GI Cancers Symposium to date. Can you comment on the 20th anniversary milestone and the impact of the symposium on GI cancers? Dr. Rachna Shroff: Absolutely, and that's so great to hear that that's the feedback that you've heard. I have to say GI ASCO is absolutely my favorite meeting of the year, so that is my full disclosure. But I think that this was a tremendous meeting, and I think it was so beautiful that it was also coinciding with the 20th anniversary. It meant so much to us to have Dr. Margaret Tempero open the meeting because she really was the impetus for creating a GI cancer-focused meeting that really brought together multidisciplinary expertise. And so to us, that is what this 20th anniversary represented—20 years of multiple different specialties coming together to discuss how to improve cancer care for patients with gastrointestinal malignancies. And it has been a transformative meeting to see the impact of research presented at this meeting and how it has been implemented over the course of 20 years. And I completely agree that this year in and of itself had some incredible pivotal data that there is no doubt will be practice-changing, and that is absolutely the purpose. I also think that the beauty of this meeting is the networking opportunities for all of us to come out of our individual silos, come together, and discuss cross-cutting care across the spectrum of GI malignancies. And I think that this meeting really did that quite well. Dr. Shaalan Beg: There were many practice-changing studies that made headlines this year, and for me, one of the most anticipated studies was a trial that you led for cholangiocarcinoma and much-anticipated results. The study finished enrollment at a record pace. Can you share your key findings of cholangiocarcinoma? And I'd really like to hear your perspective on cholangiocarcinoma studies. Dr. Rachna Shroff: Yes, it was actually a really big year in the hepatobiliary space, and I was proud to present SWOG 1815, LBA 490, which was the pivotal randomized phase 3 trial looking at gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin. This was a study that was opened across the entire NCTN and based on a single-arm phase 2 trial that had shown some promising early efficacy of the triplet chemotherapy regimen. As you mentioned, this study accrued 441 patients in two years. And it's really a testament to the fact that the cooperative group mechanism can and should be asking important questions in large, randomized studies and that it is even possible to do in what are historically thought of as, quote-unquote, “rare tumors.” The study was a randomization of two to one to the triplet chemotherapy versus the standard of care for newly diagnosed biliary tract cancer patients. And the primary endpoint was median overall survival. And while the median OS of the triplet regimen was numerically improved at 14 months compared to 12.7 months, this did not meet statistical significance. Other efficacy endpoints, including median progression-free survival and overall response rate, were also numerically improved but not statistically significant, with an overall response rate of 31% with the triplet regimen versus 22%. There were some prespecified stratification factors, including disease site and disease stage, and there may be some interesting signals that bear out of that in terms of perhaps gallbladder cancer and locally advanced patients may be benefiting from the triplet regimen a little bit more, but these are small numbers, and we would really need to explore that in a more rigorous prospective manner. The toxicities were, not surprisingly, there, especially hematologic toxicities. I will say for those of us that use this regimen in practice, we use it a little bit differently than what was done in SWOG 1815, but you can't deny that there were significantly higher grade 3-5 toxicities with anemia neutropenia and thrombocytopenia, though the treatment discontinuation rate did not differ. I think the next steps are really going to be the ongoing biomarker analyses. The study had archival tissue and prospective blood collection and we know that in the space of cholangiocarcinomas and biliary cancers, molecular complexities absolutely play a role in how patients do and how they respond to therapies. So that's going to be an important next step, I think, for this study. Dr. Shaalan Beg: Speaking of biomarkers and an impact on GI cancers, the other malignancy where biomarkers are having a much greater impact than other GI cancers is colon cancer. Another year where we continue to see advances in our understanding of molecularly targeted treatments for colon cancer. What caught your eye? Dr. Rachna Shroff: Well, there were a lot of really interesting studies happening in this space and as a biliary person, one of the first things I got excited about was seeing Abstract 139 that looked at pemigatinib, which is the drug we are very familiar with in cholangiocarcinoma. This was a single-arm phase two study looking at the use of the FGFR inhibitor pemigatinib in metastatic colorectal cancer patients who had FGFR alterations. And so this was a study that was opened through the ACCRU mechanism. It was multicenter with assignment two-stage design and it was specifically for patients with FGF and FGFR-altered metastatic colorectal cancer who had progressed on standard therapies. There was a prespecified interim analysis for futility after 12 evaluable patients and so 14 patients were enrolled in the first stage of the study and evaluated for the primary endpoint of objective response. What was seen and the study was subsequently stopped is that there was really not much efficacy, there was no evidence of safety signals, but this did not seem to be a very active drug in patients with FGFR alterations with no objective response noted. So, the study was stopped with the recognition that perhaps the FGFR translocation or fusion patient population may be something to explore since they did not look at that in this study. The other kind of study that I think is really important was important work of Dr. Raghav and colleagues through SWOG. This was SWOG 1613 Abstract 140. This was the first real study that was investigating targeting HER-2 overexpressed and amplified metastatic colorectal cancer who had RAS wild-type tumors. And it was based on, obviously, some early signals of the effectiveness of HER-2 targeting in metastatic colorectal cancer. And this was a large study looking at pertuzumab and trastuzumab in these patients. They were compared to cetuximab and irinotecan, and the initial plan was for a much larger study. Unfortunately, accrual was really slow so the study was really kind of reformatted and a total of 54 patients were randomized, 26 to the trastuzumab arm and 28 to the CetIri or cetuximab and irinotecan arm. What was seen was that you can absolutely use HER-2 targeting therapies with trastuzumab and pertuzumab in these patients. It was safe and there were some obvious signs of efficacy in terms of overall response rate with an overall response rate of 31% compared to the CetIri arm. Crossover was allowed from the CetIri arm to trastuzumab and pertuzumab. So just that's important to keep in mind when they start to follow out the survival data. But unfortunately, because this study did not accrue, it was stopped early and it's really hard to understand in terms of power calculations the impact of trastuzumab pertuzumab. Of course, we can't talk about this without recognizing that the FDA approval based on the MOUNTAINEER study for tucatinib and trastuzumab came through during GI ASCO. So clearly HER-2 targeting is here to stay in colorectal cancer. Dr. Shaalan Beg: So technology is advancing every year and it's important that we are aware of these advances and how they impact our patients. Probably one of the most exciting technologies in oncology in general is the evolution of ctDNA. And it's been amazing to watch that field unfold as we understand how to use circulating biomarkers for early detection of cancer, for minimal residual disease detection, even as a biomarker of response. What caught your eye when it comes to the use of ctDNA in GI cancers, and how do you see this space develop in the next couple of years? Dr. Rachna Shroff: I completely agree. I think the technology of ctDNA is so incredibly exciting and as somebody who does not actively see and treat colorectal cancer, I'm a little bit envious of my colleagues in that space because the strides that have been made in terms of understanding the utility of ctDNA, especially in colorectal cancer, has just been tremendous and even for the last two to three years. One perfect example of integrating that sort of technology into treatment paradigms is the PARADIGM trial, Abstract 11, which was looking at the concept of hyperselection of patients with RAS wild-type metastatic colorectal cancer who were on the PARADIGM trial which basically looked at frontline FOLFOX with panitumumab versus bevacizumab in patients with RAS wild type left-sided metastatic colorectal cancer. So, you know, the initial data from PARADIGM had demonstrated a longer median overall survival 37.9 months versus 34.3 months, but very smartly, the investigators had also collected baseline plasma ctDNA in the biomarker component of this study and used a custom panel that looked at gene alterations for hyperselection and that included KRAS, NRAS, PTEN, and extracellular domain EGFR mutations HER-2 and MET amplifications, as well as some fusions like ALK, RET, and NTRK. And so out of the 802 patients in the full set, 91% - 733 patients - actually had pretreatment samples for ctDNA, which is really in and of itself, I think, tremendous. And when you break it down, about 28% had at least one gene alteration, and that was across each of those different genes that they were looking at. In the 72% of patients who were defined as hyperselected without any gene alterations, the OS was actually longer with panitumumab versus bev, and that actually was independent of sidedness with hazard ratios that kind of ranged from 0.76 to 0.82. And OS was similar or inferior with panitumumab versus bevacizumab again, regardless of sidedness in patients with any of these gene alterations. And so I think it's a really interesting concept that you can use ctDNA to define negative hyperselection rather than looking at left sided and right sided to really help select patients with frontline therapy in terms of using panitumumab versus bevacizumab. And with the speed with which ctDNA can be obtained, this actually seems like something that could be implemented into clinical practice, which is, I think, really the important component of that. There were a number of other really interesting abstracts. Abstract 5, presented by Dr. Cohen and colleagues, really looked at the kinetics of circulating cell-free DNA and how that kind of relates to minimal residual disease detection rates. And this was in patients with resected stages one through three colorectal cancer. And so, this was a retrospective study, so we have to keep that in mind. And it was multi-institutional in really over 16,000 patients with stages 1 through 3 colorectal cancer. But the complete dataset had about 417 patients and basically the patients' circulating cell-free DNA levels, the total cfDNA, were compared to the ctDNA MRD positivity rates and they looked at very specific time points after surgery. What the authors generally found was that the postoperative cfDNA correlated well with ctDNA positivity and that there was really the ability to see plasma cfDNA levels kind of track and follow with the very specific MRD windows that were being looked at, which really, again, just kind of talks about leveraging this technology in terms of real-world and real-time application and better understanding and informing us of minimal residual disease post what is thought to be curative resection. The last one that I thought was really interesting in relation to ctDNA was actually looking at anal cancer and following ctDNA in patients who were treated with definitive chemoradiation. This was a study that was looking at 31 patients with anal squamous cell carcinoma who were treated with definitive chemo radiation and underwent ctDNA response. The majority of these patients had stage 3 disease and the majority of them received the standard 5-FU Mitomycin with radiation. The patients had ctDNA testing performed in 25 of these patients at baseline and then a smaller number over the course of time, some during chemoradiation. And then they looked again at 30 days post chemoradiation. And at baseline, 88% of patients had detectable ctDNA with those with stage three disease having numerically higher baseline ctDNA levels. And basically what they found was that over the course of treatment, ctDNA levels decreased among the patients with detectable ctDNA. And then ctDNA that tested during chemo radiation showed a drop in decline and were going into molecular remission at a time point in which it was subsequently confirmed that they had a clinical complete response. So, the suggestion here is that the time to molecular ctDNA remission was significantly shorter than being able to see that clinical complete response, which suggests that using surveillance ctDNA monitoring could be an earlier response assessment for patients with anal squamous cell carcinoma who are undergoing definitive therapy. Now, obviously this needs to be confirmed in a larger manner, but again, really suggests that we could be understanding how we're doing with treatment in more of a real-time fashion, which I just think is incredible for those of us who are making sure that we are doing and taking the right approaches for these patients. Dr. Shaalan Beg: One of the major transformative announcements that took place only a couple of months before the GI Cancer Symposium was the announcement of ChatGPT. And we heard a lot of discussion on how it can be used for improving cancer care, improving drug development, and in general, artificial intelligence and machine learning. We've been hearing these buzzwords for such a long time, to the point that a lot of people are probably just filtering it out and then this tool comes up and it makes it real. And we're seeing different people apply these technologies in different ways. But there is tremendous potential in how this technology can improve clinical trials, drug development, and early diagnosis. And luckily, we had already secured a keynote speaker, Dr. Matthew Lundgren from Nuance Communications, and he was invited to talk about artificial intelligence, machine learning, and how it applies to cancer care. I'm really curious to hear what your highlights were from his address and how you see this impacting your day-to-day, or just the ecosystem of which we're all part of. Dr. Rachna Shroff: Yeah, I will say that his keynote was really one of the highlights of the entire meeting for me. And that is coming from somebody who doesn't really know– I know who I'm speaking to, but somebody who does not truly understand the way AI is moving. And so, I was joking with him that it was like AI 101. And I really, really appreciated the way he was able to kind of speak to a crowd that he doesn't normally speak to and help us really understand the way in which artificial intelligence can be integrated into healthcare, and specifically oncology. To me, I think what were the most salient takeaways from his address was really about how this is just a rapidly evolving field and we need to be a little bit ahead of the eight ball when it comes to thinking how we can smartly leverage artificial intelligence like you mentioned, to improve our clinical research efforts, to improve access, and to improve fully integrating AI into our EMR, so that we can really leverage that technology and ensure that we are capturing every potential patient for a clinical trial and be smarter about how we're even approaching things. I mean, I loved him talking about the prior authorizations and that sort of thing, and the ways in which we can decrease the burden on health care providers and really let us focus on the areas that we need to focus on. The one thing that I thought was a really important point, though, and I think a number of people asked him, was about how using this technology has the potential to create more gaps and disparities and how can we be smart to ensure that we don't broaden those gaps. And I think that is a really important point that we all need to think about because we know that especially when we think through clinical trials, there's already underrepresentation of certain populations and certain geographic regions. And so, I think that was a really important takeaway for me is how can we make sure that we work and partner with those who are creating these technologies to ensure that we aren't taking two steps forward and four steps back. Dr. Shaalan Beg: It really calls into question how we define productivity and what our value in the entire delivery system really is. And I think from people who are in middle school or high school to people who are in college and even folks who are in the field as you and I are, it's forcing us to rethink what we bring to the table in a way that we've never been challenged to ask that question ever before. Dr. Rachna Shroff: Absolutely. Dr. Shaalan Beg: So, thank you very much, Dr. Shroff. This was wonderful. Thank you for sharing your insights with us today. And we thank you and Dr. George Chang, the chair of the ASCO GI Cancers Symposium, and everyone who worked so hard to develop a robust program this year.  Dr. Rachna Shroff: Thank you. It was so wonderful to be able to speak about it. And thank you to all of the attendees for making it such a memorable meeting. Dr. Shaalan Beg: And thank you to all our listeners for your time today. You'll find links to the abstracts discussed today on the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News podcast, please take a moment to rate, review, and subscribe wherever you get your podcast. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experiences, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers: Dr. Shaalan Beg @ShaalanBeg Dr. Rachna Shroff @rachnatshroff Follow ASCO on social media:  @ASCO on Twitter  ASCO on Facebook  ASCO on LinkedIn  Disclosures: Dr. Shaalan Beg: Employment: Science 37 Consulting or Advisory Role: Ipsen, Array BioPharma, AstraZeneca/MedImmune, Cancer Commons, Legend Biotech, Foundation Medicine Research Funding (Inst.): Bristol-Myers Squibb, AstraZeneca/MedImmune, Merck Serono, Five Prime Therapeutics, MedImmune, Genentech, Immunesensor, Tolero Pharmaceuticals Dr. Rachna Shroff: Consulting or Advisory Role: Exelixis, Merck, QED Therapeutics, Incyte, Astra Zeneca, Taiho Pharmaceutical, Boehringer Ingelheim, SERVIER, Genentech, Basilea Research Funding: Pieris Pharmaceuticals, Taiho Pharmaceutical, Merck, Exelixis, QED Therapeutics, Rafael Pharmaceuticals, Bristol-Myers Squibb, Bayer, Immunovaccine, Seagen, Novocure, Nucana, Loxo/Lilly, Faeth Therapeutics        

Nuance Communications, Inc. v. International Business Machine

December 1: Today on the Community channel, it's an Interview in Action live from HLTH with Peter Durlach, Chief Strategy Officer for Nuance Communications. What innovations are Nuance bringing to healthcare in the fields of clinical documentation, diagnostic imaging, consumer experience, virtual assistant technology and documentation integrity?Sign up for our webinar: How to Modernize Your Data Platform in Healthcare: The Right Fit for Every Unique Health System - Wednesday December 7 2022: 1pm ET / 10am PT. Subscribe: https://www.thisweekhealth.com/subscribe/Twitter: https://twitter.com/thisweekhealthLinkedin: https://www.linkedin.com/company/ThisWeekHealth

As value-based care gains traction across the healthcare landscape, clinical documentation will continue to be subject to intense scrutiny from internal and external stakeholders. Yet, healthcare organizations must take care not to exacerbate the cognitive overload and administrative burdens that plague clinicians today. Join Robert Budman, MD, MBA as he discusses the role of AI-based computer-assisted physician documentation (CAPD) technology in enhancing the accuracy of documentation and easing the burden on clinicians. On today's SoundPractice episode, Mike Sacopulos interviews Dr. Robert Budman, Chief Medical Information Officer at Nuance Communications. Board Certified in Family Medicine & Informatics, Dr. Budman focuses on efficiency, safety, and quality initiatives, with global experience in multi-EHR and service line care delivery. In his role at Nuance, he primarily supports the CAPD product line, and speaks extensively on healthcare IT. Delivered in a streamlined workflow, Nuance's proven, evidence-based guidance enables clinicians to capture complete and accurate documentation at the point of care. Discover how to drive better outcomes across the continuum of care with Nuance's portfolio of CAPD solutions, backed by sophisticated artificial intelligence. To learn more, www.nuance.com/capdLearn more about the American Association for Physician Leadership at www.physicianleaders.org  

As value-based care gains traction across the healthcare landscape, clinical documentation will continue to be subject to intense scrutiny from internal and external stakeholders. Yet, healthcare organizations must take care not to exacerbate the cognitive overload and administrative burdens that plague clinicians today. Join Robert Budman, MD, MBA as he discusses the role of AI-based computer-assisted physician documentation (CAPD) technology in enhancing the accuracy of documentation and easing the burden on clinicians. On today's SoundPractice episode, Mike Sacopulos interviews Dr. Robert Budman, Chief Medical Information Officer at Nuance Communications. Board Certified in Family Medicine & Informatics, Dr. Budman focuses on efficiency, safety, and quality initiatives, with global experience in multi-EHR and service line care delivery. In his role at Nuance, he primarily supports the CAPD product line, and speaks extensively on healthcare IT. Delivered in a streamlined workflow, Nuance's proven, evidence-based guidance enables clinicians to capture complete and accurate documentation at the point of care. Discover how to drive better outcomes across the continuum of care with Nuance's portfolio of CAPD solutions, backed by sophisticated artificial intelligence. To learn more, www.nuance.com/capd Learn more about the American Association for Physician Leadership at www.physicianleaders.org  

In this episode, Ali, Jay and Mohannad interview Dr. Woojin Kim about his chapter on Reporting in the new edition of PII. Woojin Kim, MD, is Chief Medical Officer at Equium Intelligence, a start-up he co-founded in intelligent, data-driven resource management. He is also a musculoskeletal radiologist at the VA Palo Alto, CA. Dr. Kim was the Chief Medical Information Officer at the Healthcare Division of Nuance Communications from 2016 to 2019. He was a co-founder of Montage Healthcare Solutions, acquired by Nuance in 2016. Previously, Dr. Kim had served as interim Chief of the Division of Musculoskeletal Imaging, Director of Center for Translational Imaging Informatics, and Chief of Radiography at the Hospital of the University of Pennsylvania. Dr. Kim has been an active member in imaging informatics within various societies, including ACR, SIIM, and RSNA, focusing on data mining, analytics, and machine learning. Connect with us! You can find our podcast on Apple Podcast, Google Podcasts, Stitcher, or anywhere else you subscribe to podcasts. Please help us out by leaving a review on Apple Podcasts. You can find us on Twitter: @SIIM_Tweets, and individually at @mohannadhussain, @jaynagels, @AliTejaniMD, @AAnandMD Visit us at https://siim.org/page/siimcast Special Thanks to @RandalSilvey of http://podedit.com for editing and post processing support.

Sarah Gaeta is a recognized leader in the technology space and an accomplished executive. She is the CEO of Conversion Logix, a digital marketing and technology partner that has been ranked on the Inc. 5000 list. She has held leadership positions at companies, including Adobe, Motorola, Nuance Communications, and TiVo. Additionally, Sarah serves as a consultant for other business executives to strengthen their organizational and leadership skills. In this episode… Is it possible for someone outside of the business world to be a successful leader? How can women flourish in historically male-dominated industries, and what challenges do they face?  Sarah Gaeta's career was a long and winding road before becoming a CEO and technology consultant. She started in teaching, photography, and liberal arts. However, through determination and a desire to keep growing, she found her niche in business and technology. She has faced many obstacles and learned countless lessons along the way. Now, she shares her stories and insights with you. In this episode of Next Wave Leadership, Dov Pollack interviews Sarah Gaeta, the CEO of Conversion Logix, to talk about her story and her thoughts on leadership. They start with the importance of validating employees, why she worked with a coach, and how her early life influenced her leadership style. They also discuss her struggles in the technology industry and what she learned from those who came before her.

Hello everyone and welcome to another incredible episode of the Talk2Rami "Founder's Series" Podcast, where I interview movers and shakers, as to why they do what it is exactly they do! In today's episode, I had the pleasure of sitting down with Start Up Coach, Mentor To Founders, and Fractional CEO and Founder of ExitGuide; Eric Grafstrom! With 15 years of experience from the trenches of Silicon Valley, Eric Grafstrom has worked with 20+ Venture backed start up companies in Silicon Valley under various Executive roles. He had full P&L responsibility, built & managed finance, legal, HR, sales, BD, marketing and helped raise over $20M including negotiating a $10M strategic investment from Nuance Communications and drove partnerships with Samsung, AT&T and Verizon. He shares some of his insights related to business development for early stage companies on BizDev for Startups blog! Blog: https://bizdevforstartups.com/ Learn more about Eric here: https://ericgrafstrom.com/

Today's guest is Tami McMasters Gomez, MHL, BS-HIM, CCDS, CDIP, the director of coding and CDI services at the University of California Medical Center at Davis in Sacramento. Today's show is a part of the “Leadership with Linnea” series. In every episode of this series, Associate Editorial Director Linnea Archibald be joined by one guest from the ACDIS Leadership Council ranks or a contributor from one of our ACDIS publications to discuss a topic relevant to leaders in the industry, whether or not they currently hold a traditional management title. Our intro and outro music for the ACDIS Podcast is “medianoche” by Dee Yan-Kay and our ad music is “Take Me Higher” by Jahzzar, both obtained from the Free Music Archive. Have questions about today's show or ideas for a future episode? Contact the ACDIS team at acdis-inquiries@simplifycompliance.com. Today's show is brought to you by Nuance Communications. Nuance Communications is a technology pioneer with market leadership in conversational AI and ambient intelligence. A full-service partner trusted by 77 percent of U.S. hospitals and 85 percent of the Fortune 100 companies worldwide, Nuance creates intuitive solutions that amplify people's ability to help others. ACDIS update: Celebrate ACDIS' 15th anniversary by sharing your memories and taking 15% off select ACDIS products all month! (http://ow.ly/kzaz50L3AH6 and http://ow.ly/jkov50L3AK1) Read the newly released 2022 update of the ACDIS/AHIMA Guidelines for Achieving a Complaint Query Practice brief and send in your comments! (http://ow.ly/rZSu50L3ABa) Respond to the 2022 CDI Salary Survey by October 31! (http://ow.ly/RTsh50L3APV) Apply for the ACDIS CDI Scholarship program by November 30! (http://ow.ly/pwtG50L3ARZ) 

Summer Listening - Today, ISF CEO Steve Durbin is in conversation with Brett Beranek, Vice President and General Manager of security and biometrics at Nuance Communications. Steve and Brett discuss some of the potential and the challenges of biometrics in the security space, including recent advancements in deep neural networks and deep fakes. Read the transcript of this episode Subscribe to the ISF Podcast wherever you listen to podcasts Connect with us on LinkedIn and Twitter From the Information Security Forum, the leading authority on cyber, information security, and risk management

Today's guest is Jennifer Boles, BS, CPC, CRC, CCDS-O, ambulatory CDI manager at Baptist Health Medical Group in Louisville, Kentucky, and co-hosted by Kim Conner, BSN, CCDS, CCDS-O, CDI education specialist for ACDIS/HCPro, a Simplify Compliance brand, in Middleton, Massachusetts. Today's show is a part of the “Leadership with Linnea” series. In every episode of this series, Associate Editorial Director Linnea Archibald be joined by one guest from the ACDIS Leadership Council ranks or a contributor from one of our ACDIS publications to discuss a topic relevant to leaders in the industry, whether or not they currently hold a traditional management title. Our intro and outro music for the ACDIS Podcast is “medianoche” by Dee Yan-Kay and our ad music is “Take Me Higher” by Jahzzar, both obtained from the Free Music Archive. Have questions about today's show or ideas for a future episode? Contact the ACDIS team at acdis-inquiries@simplifycompliance.com. Today's show is brought to you by Nuance Communications. Nuance Communications is a technology pioneer with market leadership in conversational AI and ambient intelligence. A full-service partner trusted by 77 percent of U.S. hospitals and 85 percent of the Fortune 100 companies worldwide, Nuance creates intuitive solutions that amplify people's ability to help others. ACDIS update: 2023 ACDIS national conference and December outpatient CDI virtual event speaker application open till August 19! (http://ow.ly/wC4E30snuK7) CDI Week 2022 resources (http://ow.ly/CkPG30soWFj) ACDIS Leadership Council applications open till August 31! (https://www.surveymonkey.com/r/2022-2023-Council-application) In memoriam of Melissa Varnavas and form to send memories, photos, and condolences to her family (http://ow.ly/ciz150Kl3Ao) 

Our guest is world-famous and while you may not heard of her, you may have heard her voice!Aussie-born and now back in Australia, Karen Jacobsen's speaking voice is in over 1 Billion GPS units and smartphones worldwide giving directions.From a single voice-over booking, she created her empowerment brand “The GPS Girl”, teaching the five directions for “recalculating" in business and life.An award-winning Singer and Songwriter, Karen's musical career highlights include sharing the bill with Norah Jones, Neil Sedaka and Christopher Cross and singing the national anthem at major sporting events including 80,000 people at the Giants Stadium for the New York Jets.A TEDx speaker, Karen has enjoyed wide media coverage including the NBC Today Show, ABC World News Tonight, the CBS Early Show, The New York Times, NY Daily News, Glamour magazine, being named one of People Magazine's Most Intriguing People and she hosted her own web series "Navigating New York with The GPSGirl".Karen's voice is in demand in the studio as a Voice-Over artist recording customised voice systems and advertising campaigns and in-person as an entertainer and speaker for Corporate events around the globe.As an Author, Karen's book "The GPS Girl's Road Map for Your Future” gives direction for getting more of what you want in business and life.We covered a range of topics includingKaren's Hero: Olivia Newton-JohnHow Karen became "Aussie Karen" in SiriHow the recording process workedHow Karen uses voice interfaces in real lifeWill AI replace the human voice assistant completely?The time Karen found out she was the voice behind "Aussie Karen"Karen's Son's reaction to his mummy being in her phoneKaren's most interesting voiceover jobThe GPS Girl and corporate audiences on recalculatingTransferrable skills from a signer to a corporate presenterThe new reality of performing in a post-covid worldAdvice for people wanting to perform as a singer or speaker and how to build confidenceTips for improving your public speakingHow Karen recalculated in March 2020Karen's new life in The Whitsundays, AustraliaThe blueprint for a real ambassadorThe magic about The WhitsundaysThree Actionable tips for recalculating your next destinationResources mentioned on the showA Passionate Life - Ita ButroseTourism WhitsundaysOlivia Newton-JohnMore on KarenKaren on LinkedInKaren on TwitterKaren's Music WebsiteThe GPS GirlYour Host: Actionable Futurist® Andrew GrillFor more on Andrew - what he speaks about and replays of recent talks, please visit ActionableFuturist.com follow @AndrewGrill on Twitter or @andrew.grill on Instagram.

I've always been fascinated by how technology can improve healthcare, and over the years at my keynote talks, audiences have asked me for my view of what's next.Finally, I managed to grab two leading figures on this subject: Dr Simon Wallace, Chief Clinical Information Officer at Nuance Communications, and Umang Patel, Chief Clinical Information Officer at Microsoft to help explain this important topic.Simon is a GP & public health doctor providing consultancy services to healthcare organisations. He has 20 years of commercial experience modernising & improving the delivery of healthcare. Previously he was at Hutchison 3G, AXA,  GSK & Worldcare UK.Umang has worked across commercial and public sectors in healthcare both from payor and provider perspectives and was an early employee at Babylon Health, commercial leader at Aviva, and a NHS Leadership Academy Fellow and practising clinician at Frimley Health.On the back of the news that Microsoft has agreed to acquire Nuance Communications for $19.7 billion and the transaction is now approved and complete, I spoke to Simon and Umang about how significant this alliance is for the future of digital health.They are both passionate clinicians and have a deep understanding of how healthcare will be improved with the use of the latest technologies.I managed to ask many of my "What's the future of healthcare" questions I've wanted to ask for a while, and also confirmed some of my futurist predictions.In this wide-ranging chat, we covered:The Nuance & Microsoft AllianceNuance & conversational AIFuture health plans from MicrosoftCan technology restore the NHS to full health?Open data vs patient privacyThe power of AI in transforming healthcareWhat we've learned from the pandemic about driving innovationThe success of the NHS appImporting fitness data into health systemsThe untapped power of speech & AI in healthcareWhat does the Healthcare Professional of the future look like?What does the Hospital of the future look like?The promise of a "digital pill"Using voice to establish patient wellbeingSimon's & Umang's proudest projects3 Actionable things to better understand the benefits of digital health solutionsResources mentioned on the showUnited Nation The Case for Integrating IrelandBetter Off Dead: Jack ReacherKaren Jacobsen - "Aussie Karen" Siri voiceMore on our guestsSimon on LinkedinUmang on LinkedinUmang on TwitterNuance websiteMicrosoft Cloud for Healthcare WebsiteYour Host: Actionable Futurist® Andrew GrillFor more on Andrew with replays of recent talks, please visit ActionableFuturist.com and follow @AndrewGrill on Twitter or @andrew.grill on Instagram.

Plannuh is a marketing performance planning platform. It's a system for building, managing and optimizing marketing plans and it's another SaaS tool that's killing the spreadsheet. We catch up with CEO and Founder Peter Mahoney; he's an absolute powerhouse marketer with incredible experience and knowledge on all things martech. He got his start at IBM and spent over a decade at Nuance Communications before founding Plannuh. Peter has amazing insights into the stack's security vulnerabilities. Every company should be aware that the biggest threat to the security of your organization is the marketer. You should consider only buying tools for your stack that are ISO or Soc 2 certified; but as we'll discuss even these certifications have their limitations. We'll talk about the importance of specialists for complex implementations and why so many companies end up using only 10% of the capacity of a given tool. We'll also hear how AI can enrich the predictive power of your stack, and why Peter thinks this will be one of the biggest technology trends we'll see in coming years. Join us every week as we journey to the bleeding edge of the modern tech stack. You'll hear from real experts on how to nail your strategy, build a revenue machine and take your sales to the next level.

Today, our guest is Brett Beranek, VP and General Manager for Security and Biometrics at Nuance Communications. For an AI company, Nuance is relatively large. Microsoft recently bought the company for over $30B, and they serve a variety of industries. Our topic today is the importance of subject-matter experts. Brett provides essential insights regardless of your industry because subject-matter experts play an important role in AI adoption. Within Emerj Plus, we have a long executive guide on the importance of subject-matter experts, and this interview will provide a lot of richness and depth on top of that from first-hand experience. If you're interested in learning more about Emerj Plus and how to unlock our AI best practice guides, frameworks for AI ROI, and specific resources for enterprise leaders, visit emerj.com/p1.

Today, ISF CEO Steve Durbin is in conversation with Brett Beranek, Vice President and General Manager of security and biometrics at Nuance Communications. Steve and Brett discuss some of the potential and the challenges of biometrics in the security space, including recent advancements in deep neural networks and deep fakes. Read the transcript of this episode Subscribe to the ISF Podcast wherever you listen to podcasts Connect with us on LinkedIn and Twitter From the Information Security Forum, the leading authority on cyber, information security, and risk management

Kenneth Harper, Vice President, General Manager of Ambient Clinical Intelligence and Virtual Assistants and Dr. Hal Baker, Senior Vice President Chief Digital and Chief Information Officer of WellSpan, join me to talk about new technology that allows doctors to better connect with patients to capture the full patient story.

This week's guest is Brett Beranek, Vice-President & General Manager of Security & Biometrics Line of Business at Nuance Communications. In today's episode, Brett speaks with us about the fraud-related trends in the financial services industry as a result of COVID and some of the concrete use-cases we could consider to address them moving forward. He first speaks specifically about the industry trends related to fraud and paints a picture of how fraud is shifting at a high level before diving into a concrete use-case more deeply. To learn more about the methods for finding AI trends that will allow you to stay ahead of the curve, download our whitepaper “3 Ways to Discover AI Trends” at emerj.com/t3.

Today's episode is a Simply Tech LIVE interview recorded May 6th, of this year 2021, featuring my co-host, Ali Mazaheri, and our special guests, coming to us from Microsoft's High Tech Pursuits Unicorn Team - a special team focused on accelerating, partnering, and supporting the enterprise of the future.The discussion will feature Ken Miller, GM of Microsoft's West Region Intelligent Cloud team and leader of the Unicorn team we're talking with today. Shaloo Garg will be joining us in the discussion, Shaloo is the Managing Director of Growth Stage Startups and Unicorns at Microsoft. We'll also be featuring Matt Hughes in the discussion, Matt is a High Tech industry leader at Microsoft, and the combination of these (3) guests will cover a vast array of really fun, top of mind, and critical topics across the high tech industry, and, how value will be, and continues to be captured and developed with founders, venture capitalists, and new joint partnerships in the world of fast moving and emerging technologies.If you have any interest in the future landscape of emerging tech as a founder, an investor, or an organization looking to seek differentiated ways to think about the growth stage and unicorn ecosystem, you will very much enjoy this conversation. Thank you for listening, and now we bring you Microsoft's High-Tech Pursuits Unicorn Team.Key Take-aways:[09:32] High tech trends and transformations across the technology industry [12:00] Exciting tech related market making partnerships and acquisitions[13:31] Social impact and other emerging technology industry headwinds to pay attention to[15:23] High tech at Microsoft – what is means, who are the customers, and what the future enterprise looks like[20:21] Additional forecasts for market needs and opportunities in the high tech space[25:26] What consumers demand from the high-tech industry and how the consumer is shaping innovation[27:51] The Microsoft ecosystem and support environment for high tech organizations[32:53] Transformational change across business and culture: how to navigate, cope, and seize net new opportunities[38:47] Microsoft's Unicorn Initiative and thematic areas that empower the Start-up[41:37] Shaloo's experience as a woman leader at Microsoft, and women founder perspectives in the growth stage start up eco-system[46:18] Why founders should think about partnering with Microsoft[51:43] Advice and guidance for women founders[55:39] Discussions around engaging across the high-tech community, and opportunities to discover innovation through the Microsoft Technology Centers Resources:Contact our guests:Ken Miller: https://www.linkedin.com/in/millerken/Shaloo Garg: https://www.linkedin.com/in/shaloo-garg/Matt Hughes: https://www.linkedin.com/in/matthughes4/The Marsen Group - https://blogs.microsoft.com/blog/2021/03/16/microsoft-acquires-the-marsden-group-a-leader-in-rapid-industry-innovation/Nuance Communications - https://news.microsoft.com/2021/04/12/microsoft-accelerates-industry-cloud-strategy-for-healthcare-with-the-acquisition-of-nuance/What Is a Special Purpose Acquisition Company (SPAC)? https://www.investopedia.com/terms/s/spac.aspMicrosoft Technology Centers - https://www.microsoft.com/en-us/mtc *The views and opinions expressed in this discussion are those of the guests and do not necessarily reflect the official position of their employer, Microsoft" ____ Thank you for listening! -------------------------------- Join the **New Monthly Newsletter** - Data Binge REFRESH: https://www.derekwesleyrussell.com/newsletter Interested in starting your own podcast? Some candid advice here: https://www.linkedin.com/pulse/how-start-podcast-3-step-gono-go-beginners-guide-derek-russell Learn more about the Data Binge Podcast at www.thedatabinge.com Connect with Derek: LinkedIn: https://www.linkedin.com/in/derekwesleyrussell/Youtube: https://www.youtube.com/channel/UCN1c5mzapLZ55ciPgngqRMg/featuredInstagram: https://www.instagram.com/drussnetwork/Twitter: https://twitter.com/drussnetworkMedium: https://medium.com/@derekwesleyrussellEmail: derek@thedatabinge.com *The views and opinions expressed in this discussion are those of the guests and do not necessarily reflect the official position of their employer, Microsoft"  ____ Thank you for listening! -------------------------------- Join the **New Monthly Newsletter** - Data Binge REFRESH: https://www.derekwesleyrussell.com/newsletter   Interested in starting your own podcast? Some candid advice here: https://www.linkedin.com/pulse/how-start-podcast-3-step-gono-go-beginners-guide-derek-russell  Learn more about the Data Binge Podcast at www.thedatabinge.com   Connect with Derek: LinkedIn: https://www.linkedin.com/in/derekwesleyrussell/Youtube: https://www.youtube.com/channel/UCN1c5mzapLZ55ciPgngqRMg/featured Instagram: https://www.instagram.com/drussnetwork/ Twitter: https://twitter.com/drussnetwork Medium: https://medium.com/@derekwesleyrussell Email: derek@thedatabinge.com